Parallax Health Sciences Competitors

Parallax Health Sciences (OTCMKTS:PRLX) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Parallax Health Sciences and Olink Holding AB (publ), as reported by MarketBeat.com.

Profitability

This table compares Parallax Health Sciences and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Parallax Health Sciences and Olink Holding AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Ortho Clinical Diagnostics (NASDAQ:OCDX) and Parallax Health Sciences (OTCMKTS:PRLX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Earnings & Valuation

This table compares Ortho Clinical Diagnostics and Parallax Health Sciences' top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations for Ortho Clinical Diagnostics and Parallax Health Sciences, as reported by MarketBeat.

Ortho Clinical Diagnostics currently has a consensus target price of $24.2727, indicating a potential upside of 25.12%. Given Ortho Clinical Diagnostics' higher possible upside, equities research analysts plainly believe Ortho Clinical Diagnostics is more favorable than Parallax Health Sciences.

Profitability

This table compares Ortho Clinical Diagnostics and Parallax Health Sciences' net margins, return on equity and return on assets.

Summary

Ortho Clinical Diagnostics beats Parallax Health Sciences on 2 of the 2 factors compared between the two stocks.

Parallax Health Sciences (OTCMKTS:PRLX) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Valuation and Earnings

This table compares Parallax Health Sciences and Biodesix's revenue, earnings per share and valuation.

Profitability

This table compares Parallax Health Sciences and Biodesix's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Parallax Health Sciences and Biodesix, as reported by MarketBeat.

Biodesix has a consensus target price of $26.00, indicating a potential upside of 35.28%. Given Biodesix's higher possible upside, analysts plainly believe Biodesix is more favorable than Parallax Health Sciences.

Summary

Biodesix beats Parallax Health Sciences on 2 of the 2 factors compared between the two stocks.

Lucira Health (NASDAQ:LHDX) and Parallax Health Sciences (OTCMKTS:PRLX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Lucira Health and Parallax Health Sciences, as provided by MarketBeat.com.

Lucira Health presently has a consensus target price of $22.00, suggesting a potential upside of 104.65%. Given Lucira Health's higher probable upside, research analysts clearly believe Lucira Health is more favorable than Parallax Health Sciences.

Earnings & Valuation

This table compares Lucira Health and Parallax Health Sciences' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Lucira Health and Parallax Health Sciences' net margins, return on equity and return on assets.

Summary

Lucira Health beats Parallax Health Sciences on 2 of the 2 factors compared between the two stocks.

Akumin (NASDAQ:AKU) and Parallax Health Sciences (OTCMKTS:PRLX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Akumin and Parallax Health Sciences, as reported by MarketBeat.com.

Institutional and Insider Ownership

30.4% of Akumin shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Akumin and Parallax Health Sciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Akumin and Parallax Health Sciences' gross revenue, earnings per share (EPS) and valuation.

Summary

Akumin beats Parallax Health Sciences on 2 of the 2 factors compared between the two stocks.

Parallax Health Sciences (OTCMKTS:PRLX) and Inotiv (NASDAQ:NOTV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Profitability

This table compares Parallax Health Sciences and Inotiv's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Parallax Health Sciences and Inotiv's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and price targets for Parallax Health Sciences and Inotiv, as provided by MarketBeat.